Scrip100: Indian firms up R&D spend, ascend value chain
This article was originally published in Scrip
The R&D spends of a clutch of frontline Indian firms have seen a significant uptick over the past few years, seemingly in line with their growing emphasis on complex therapy and limited competition areas as well as the efforts of some to make a mark in the biosimilars space.
You may also be interested in...
A COVID-19 second wave is wreaking havoc in India but pharma appears to be holding things together for now, stretching resources amid a dip in personnel attendance and supply chain strains. Limited vaccine supplies, a spurt in API prices and an inevitable third wave could mean further turbulence ahead.
Eli Lilly responds with baricitinib donation plan and efforts to sew up royalty free voluntary licenses with local Indian firms as challenger Natco seeks a compulsory license for its version of the JAK inhibitor, which it is ready to launch.
Biocon is still awaiting a site inspection as pandemic-related delays keep its Viatris-partnered bevacizumab out of the US market, though the Indian company believes it can still make good and garner market share. All eyes are also on traction for its insulin glargine via increased share of formulary contracts.